Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected - Genesis Health System

Lung (Non-Small Cell) Cancer: A081105

Alliance A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Objective

The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

This study is for patients that participated in the A151216 screening study and were found to have a mutation of a gene called EGFR (Epidermal Growth Factor Receptor). We are trying to find out if this mutation could help us make decisions about what type of treatment is best for people with early stage non-small cell lung cancer.

This study is related to the following study - A151216.

For more information, please visit the National Cancer Institute.

LOCATIONS:

1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Sponsor(s)
Alliance for Clinical Trials in Oncology
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email